PMID- 22903723
OWN - NLM
STAT- MEDLINE
DCOM- 20121217
LR  - 20231213
IS  - 1940-6029 (Electronic)
IS  - 1064-3745 (Linking)
VI  - 909
DP  - 2012
TI  - Discovery of lamin B1 and vimentin as circulating biomarkers for early 
      hepatocellular carcinoma.
PG  - 295-310
LID - 10.1007/978-1-61779-959-4_19 [doi]
AB  - The recent advancements in proteomic technologies have reconstituted our research 
      strategies over different type of liver diseases including hepatocellular 
      carcinoma (HCC). Combined analyses on HCC proteome and clinicopathological data 
      of patients have allowed identification of many promising biomarkers that can be 
      further developed into noninvasive diagnostic assays for cancer surveillance. 
      Capitalizing our established proteomic platform primarily based on 
      two-dimensional polyacrylamide gel electrophoresis (2DE) and MALDI-TOF/TOF mass 
      spectrometry, our groups have identified lamin B1 (LMNB1) and vimentin (VIM) as 
      promising biomarkers for detection of early HCC. Protein levels of both 
      biomarkers were significantly elevated in cancerous tissues when compared to the 
      controls in disease-free and cirrhotic liver subjects. Further investigation of 
      the circulating LMNB1 mRNA level in patients' blood samples by standard PCR 
      showed 76% sensitivity and 82% specificity for detection of early HCC. In 
      parallel, an ELISA assay for measuring circulating vimentin level in patients' 
      serum samples could detect small HCC at 40.91% sensitivity and 87.5% specificity. 
      The candidate biomarkers were evaluated with the diagnostic performance of 
      alpha-fetoprotein (AFP) for HCC. In this article, we address the current protocols 
      for HCC biomarker discovery, ranging from clinical sample preparation, 2DE 
      proteomic profiling and informatics analysis, and assay development and clinical 
      validation study. Focus is emphasized on the methods for sample preservation and 
      low-abundance protein enrichment.
FAU - Wong, Kwong-Fai
AU  - Wong KF
AD  - Cancer Science Institute of Singapore, National University of Singapore, 
      Singapore, Singapore.
FAU - Luk, John M
AU  - Luk JM
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Methods Mol Biol
JT  - Methods in molecular biology (Clifton, N.J.)
JID - 9214969
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Lamin Type B)
RN  - 0 (RNA, Messenger)
RN  - 0 (Vimentin)
RN  - EC 3.4.21.4 (Trypsin)
SB  - IM
MH  - Biomarkers, Tumor/*blood/chemistry/isolation & purification
MH  - Calibration
MH  - Carcinoma, Hepatocellular/*blood/diagnosis
MH  - Case-Control Studies
MH  - Early Detection of Cancer
MH  - Electrophoresis, Gel, Two-Dimensional
MH  - Enzyme-Linked Immunosorbent Assay/standards
MH  - Humans
MH  - Lamin Type B/*blood/genetics/isolation & purification
MH  - Laser Capture Microdissection
MH  - Liver/metabolism
MH  - Liver Neoplasms/*blood/diagnosis
MH  - Proteolysis
MH  - RNA, Messenger/blood
MH  - Reference Standards
MH  - Trypsin/chemistry
MH  - Vimentin/*blood/chemistry/isolation & purification
EDAT- 2012/08/21 06:00
MHDA- 2012/12/18 06:00
CRDT- 2012/08/21 06:00
PHST- 2012/08/21 06:00 [entrez]
PHST- 2012/08/21 06:00 [pubmed]
PHST- 2012/12/18 06:00 [medline]
AID - 10.1007/978-1-61779-959-4_19 [doi]
PST - ppublish
SO  - Methods Mol Biol. 2012;909:295-310. doi: 10.1007/978-1-61779-959-4_19.